Literature DB >> 21050973

Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.

Ge Gao1, Zhe Zheng, Yi Pi, Bin Lu, Jinguo Lu, Shengshou Hu.   

Abstract

OBJECTIVES: We sought to evaluate the effect of aspirin plus clopidogrel versus aspirin alone on saphenous vein graft occlusion at 3 months after coronary artery bypass grafting (CABG).
BACKGROUND: Prevalence of graft occlusion is high after CABG. Aggressive antiplatelet therapy is expected to improve early post-operative graft patency.
METHODS: From December 2007 through December 2008, 249 consecutive patients undergoing elective CABG at Fuwai Hospital were randomly assigned to 2 groups: 124 received aspirin (100 mg) plus clopidogrel (75 mg) daily (AC group), and 125 received aspirin (100 mg) alone daily (A group). Antiplatelet therapies were initiated when post-operative chest tube drainage was ≤ 30 cc/h for 2 h. All participants were invited for clinical follow-up and 64-slice multislice computed tomography angiography (MSCTA) analysis at 3 months post-operatively. Generalized estimating equations analysis was used to determine predictors of graft patency.
RESULTS: One participant, from group A, died before 3-month follow-up. Of the remaining 248 patients, 224 (90.3%) underwent MSCTA. Participants had similar pre-operative and intraoperative characteristics at baseline. No significant differences were observed in intraoperative transit-time flow measurement findings or major adverse cardiac-related events. Three-month MSCTA follow-up revealed that saphenous vein graft patency was 91.6% (219 of 239) in the AC group versus 85.7% (198 of 231) in the A group (p = 0.043). In multivariate analysis, combined antiplatelet therapy independently increased venous graft patency (p = 0.045).
CONCLUSIONS: Aspirin plus clopidogrel is more effective in venous graft patency than aspirin alone in the short term after CABG, but further, long-term study is needed. (The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease; NCT00776477).
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21050973     DOI: 10.1016/j.jacc.2010.03.104

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  30 in total

1.  Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.

Authors:  Connie N Hess; Renato D Lopes; C Michael Gibson; Rebecca Hager; Daniel M Wojdyla; Brian R Englum; Michael J Mack; Robert M Califf; Nicholas T Kouchoukos; Eric D Peterson; John H Alexander
Journal:  Circulation       Date:  2014-09-26       Impact factor: 29.690

2.  Doubling up on antiplatelet therapy after CABG: changing practice ASAP after DACAB?

Authors:  Daniel J F M Thuijs; Milan Milojevic; Stuart J Head
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

3.  CT angiography for coronary graft assessment.

Authors:  Carl Chartrand-Lefebvre; Louis-Mathieu Stevens; Samer Mansour; Nicolas Noiseux
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 4.  Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials.

Authors:  Santiago Palacio; Robert G Hart; Lesly A Pearce; Oscar R Benavente
Journal:  Stroke       Date:  2012-08       Impact factor: 7.914

5.  Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting.

Authors:  Judson B Williams; Renato D Lopes; Gail E Hafley; T Bruce Ferguson; Michael J Mack; C Michael Gibson; Robert A Harrington; Eric D Peterson; Peter K Smith; Rajendra H Mehta; John H Alexander
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

6.  Hospital Variability Drives Inconsistency in Antiplatelet Use After Coronary Bypass.

Authors:  Jared P Beller; William Z Chancellor; J Hunter Mehaffey; Robert B Hawkins; Matthew R Byler; Alan M Speir; Mohammed A Quader; Andy C Kiser; Leora T Yarboro; Gorav Ailawadi; Nicholas R Teman
Journal:  Ann Thorac Surg       Date:  2020-02-11       Impact factor: 4.330

7.  Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery.

Authors:  Renato D Lopes; Rajendra H Mehta; Gail E Hafley; Judson B Williams; Michael J Mack; Eric D Peterson; Keith B Allen; Robert A Harrington; C Michael Gibson; Robert M Califf; Nicholas T Kouchoukos; T Bruce Ferguson; John H Alexander
Journal:  Circulation       Date:  2012-01-11       Impact factor: 29.690

Review 8.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

9.  Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Maurizio Giuseppe Abrignani; Marco Ambrosetti; Nadia Aspromonte; Gabriella Barile; Roberto Caporale; Giancarlo Casolo; Emilia Chiuini; Andrea Di Lenarda; Pompilio Faggiano; Domenico Gabrielli; Giovanna Geraci; Alessio Gaetano La Manna; Aldo Pietro Maggioni; Alfredo Marchese; Ferdinando Maria Massari; Gian Francesco Mureddu; Giuseppe Musumeci; Federico Nardi; Antonio Vittorio Panno; Roberto Franco Enrico Pedretti; Massimo Piredda; Enrico Pusineri; Carmine Riccio; Roberta Rossini; Fortunato Scotto di Uccio; Stefano Urbinati; Ferdinando Varbella; Giovanni Battista Zito; Leonardo De Luca
Journal:  Eur Heart J Suppl       Date:  2018-05-31       Impact factor: 1.803

10.  Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.

Authors:  Qiang Zhao; Yunpeng Zhu; Zhiyun Xu; Zhaoyun Cheng; Ju Mei; Xin Chen; Xiaowei Wang
Journal:  JAMA       Date:  2018-04-24       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.